Another meta‐analysis of six large trials (TEAM, ATAC, BIG 1–98, SOFT, TEXT, ALTTO) in 5390 women (45% premenopausal) with HR+/HER2+ breast cancer conversely showed no significant DFS difference between an AI and tamoxifen. The gene discussed is ERBB2; the disease is breast carcinoma.